2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. MEK

MEK

Mitogen-activated protein kinase kinase; MAPKK; MAP2K

MEK

Related Products

PDF 1.0 MB

MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs). The activated MAPK leads to the phosphorylation of downstream transcription factors that regulate various responses such as stress signaling, pathogen response, and hormone signaling.

In general, the MAPKKK phosphorylates a serine or threonine residue on a MAPKK, which sequentially activates a MAPK (ERK, p38 or JNK), the last protein in the cascade. Activation of the p38 MAPK occurs mainly through mitogen-activated protein kinase kinase 3 (MKK3) and MKK6 (sometimes MKK4). The JNK is regulated by two upstream MAP2Ks: MKK4 and MKK7. The highly homologous kinases, MEK1 and MEK2, act downstream of Ras and Raf to activate ERK mitogen-activated protein kinases.

MEK Isoform Specific Products:

MEK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-112477A
    (E/Z)-Chk2-IN-1
    		Inhibitor
    (E/Z)-Chk2-IN-1 ((E/Z)-Hymenialdisine analogue-1) (Compound 1) is a potent and selective cell cycle kinase Chk2 inhibitor with an IC50 of 8 nM. (E/Z)-Chk2-IN-1 exhibits low inhibitory activity against other kinases (such as CK1δ, MEK1, and PKCα/βⅡ) with IC50 values both >89 nM. (E/Z)-Chk2-IN-1 can be used for the research of cancer.
    (E/Z)-Chk2-IN-1
  • HY-179424
    PROTAC HIF-1α degrader-2
    		Inhibitor
    PROTAC HIF-1α degrader-2 is a highly efficient and selective PROTAC degrader targeting HIF-1α. PROTAC HIF-1α degrader-2 promotes HIF-1α degradation via the ubiquitin-proteasome pathway by facilitating the formation of a HIF-1α/VHL ternary complex. PROTAC HIF-1α degrader-2 inhibits HeLa cell proliferation, migration, and colony formation, and induces apoptosis. PROTAC HIF-1α degrader-2 reduces p-MEK and p-AKT expression in the MAPK and PI3K/AKT pathways. PROTAC HIF-1α degrader-2 can be used for the study of cervical cancer.
    PROTAC HIF-1α degrader-2
  • HY-E70746
    MEK1 SESE Recombinant Human Active Protein Kinase
    MEK1 is the MAP/ERK kinase. The MEK1 kinase directly phosphorylates ERK2, after the activation loop of MEK1 is itself phosphorylated by Raf. MEK1 SESE is a mutant of MEK1. MEK1 SESE Recombinant Human Active Protein Kinase is a recombinant MEK1 SESE protein that can be used to study MEK1 SESE-related functions.
    MEK1 SESE Recombinant Human Active Protein Kinase
  • HY-183856
    MEK4 IN-4
    		Inhibitor
    MEK4 IN-4 is a MEK4 inhibitor (IC50 = 0.041 μM) that inhibits the kinase catalytic activity of MEK4 via competitive blockade of ATP binding. MEK4 IN-4 can be used to investigate cell proliferative diseases and disorders associated with MEK4 activity, including cancer.
    MEK4 IN-4
  • HY-13303
    RO 4927350
    		Inhibitor
    RO 4927350 is a potent and selective non-ATP-competitive MEK1/2 inhibitor. RO 4927350 exhibits significant antitumor efficacy in a broad spectrum of tumor models.
    RO 4927350
  • HY-145701
    MEK1/2-IN-2
    		Inhibitor
    MEK1/2-IN-2 is a potent ATP-competitive MEK1/2 inhibitor and shows equipotent inhibition of WT MEK1/2 and a panel of MEK1/2 mutant cell lines.
    MEK1/2-IN-2
  • HY-N0776R
    Isorhamnetin (Standard)
    		Inhibitor
    Isorhamnetin (Standard) is the analytical standard of Isorhamnetin. This product is intended for research and analytical applications. Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3K.
    Isorhamnetin (Standard)
  • HY-E70747
    MEK5 Recombinant Human Active Protein Kinase
    MEK5 Recombinant Human Active Protein Kinase is a MAP/ERK kinase. MEK5 is thought to lie in an uncharacterized MAP kinase pathway, because MEK5 does not phosphorylate the ERK/MAP kinase family members ERK1, ERK2, ERK3, JNK/SAPK, or p38/HOG1, nor will Raf-1, c-Mos, or MEKK1 highly phosphorylate it.
    MEK5 Recombinant Human Active Protein Kinase
  • HY-172155
    MEK1-IN-1
    		Inhibitor
    MEK1-IN-1 (Compound M15) is a MEK1 inhibitor with an IC50 of 10.29 nM. MEK1-IN-1 can inhibit the proliferation and migration, induce apoptosis of tumor cells. MEK1-IN-1 has good liver microsomal stability. MEK1-IN-1 can be used for the research of solid tumors.
    MEK1-IN-1
  • HY-164400
    SIJ1777
    		Inhibitor
    SIJ1777 is a GNF-7 (HY-10943) derivative, possesses potent anti-cancer effects on melanoma cells harboring BRAF class I/II/III mutations. SIJ1777 substantially inhibits the activation of MEK, ERK, and AKT. SIJ1777 remarkably induces apoptosis and significantly blocks migration, invasion, and anchorage-independent growth of melanoma cells harboring BRAF class I/II/II mutations.
    SIJ1777
  • HY-E70842
    MAP2K1 L115P Recombinant Human Active Protein Kinase
    MAP2K1 (also known as MEK1) is downstream of the RAF family and activation results in ERK1/2 activation. Activating mutations in MAP2K1 have been reported almost exclusively in exons 1 and 2 in both hematologic malignancies. MAP2K1 L115P is a mutant of MAP2K1. MAP2K1 L115P Recombinant Human Active Protein Kinase is a recombinant MAP2K1 L115P protein that can be used to study MAP2K1 L115P-related functions.
    MAP2K1 L115P Recombinant Human Active Protein Kinase
  • HY-181978
    GIT1-IN-1
    		Inhibitor
    GIT1-IN-1 is an inhibitor of ARF GTPase-activating protein 1 (GIT1) with a KD of 6.2 μM. GIT1-IN-1 induces apoptosis (apoptosis) in liver and colon cancer cells, arrests the cell cycle at the G2/M phase, and inhibits cell proliferation, colony formation and migration. GIT1-IN-1 inhibits the activities of MEK and ERK, reduces the expression level of cyclin D1, and stabilizes cyclin B1 protein in liver and colon cancer cells. GIT1-IN-1 can be used in the research of liver cancer and colon cancer.
    GIT1-IN-1
  • HY-13078S
    Cobimetinib-13C6 racemate
    		Inhibitor
    Cobimetinib-13C6 (GDC-0973-13C6; XL518-13C6) racemate is the deuterium labeled Cobimetinib (racemate) (HY-13078). Cobimetinib racemate (GDC-0973 racemate; XL518 racemate) is the racemate of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor.
    Cobimetinib-<sup>13</sup>C<sub>6</sub> racemate
  • HY-168288
    MEK ligand-2
    		Inhibitor
    MEK ligand-2, a MEK1 and MEK2 inhibitor, is a ligand for target protein for PROTAC of MS934 (HY-153863). MS934 is a VHL-recruiting MEK 1/2 PROTAC degrader.
    MEK ligand-2
  • HY-172803
    Ferroptosis inducer-7
    		Activator
    Ferroptosis inducer-7 is an orally active and selective ferroptosis inducer via inositol 1,4,5-trisphosphate receptor (IP3R)/calcium release-activated calcium channel protein (ORAI). Ferroptosis inducer-7 exhibits a notable effect in alleviating anemia symptoms, suppressing bone marrow CTLs activation, and improving hematopoietic function in immune-mediated bone marrow failure. Ferroptosis inducer-7 can be studied in research for aplastic anemia.
    Ferroptosis inducer-7
  • HY-14584
    PQ-1
    		Modulator
    PQ-1 is a gap junction enhancer.
    PQ-1
  • HY-175235
    MEK4 IN-3
    		Inhibitor
    MEK4 IN-3 (Compound 39) is a selective MEK4 inhibitor with IC50s of 78   and 2920 nM for MEK4 and RSK4, respectively. MEK4 IN-3 reduces toxicity in cells. MEK4 IN-3 can be used for liver failure, particularly nonalcoholic fatty liver disease (NAFLD) research.
    MEK4 IN-3
  • HY-RS08037
    Map2k2 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Map2k2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Map2k2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Map2k2 Mouse Pre-designed siRNA Set A
  • HY-RS08036
    MAP2K2 Human Pre-designed siRNA Set A
    		Inhibitor

    MAP2K2 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP2K2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    MAP2K2 Human Pre-designed siRNA Set A
  • HY-N13009
    MO-2097
    		Inhibitor
    MO-2097 is a RAF-1/HIF-1α inhibitor. MO-2097 induces RAF-1 destabilization, leading to a reduction in EMT-associated transcription factors and mesenchymal markers. MO-2097 inhibits HIF-1a protein expression mediated by hnRNPA2B1 under hypoxic and mimetic hypoxia. MO-2097 induces mitochondrial ROS, which leads to apoptosis in cells. MO-2097 effectively suppresses colorectal cancer metastasis by inhibiting the RAF/MEK/ERK signaling pathway. MO-2097 attenuates tumor growth in a xenograft HCT116 cell mouse model. MO-2097 can be used for the study of colorectal cancer.
    MO-2097
Cat. No. Product Name / Synonyms Application Reactivity
MEK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.